| __timestamp | Ligand Pharmaceuticals Incorporated | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 17986000 |
| Thursday, January 1, 2015 | 24378000 | 32480000 |
| Friday, January 1, 2016 | 26621000 | 68081000 |
| Sunday, January 1, 2017 | 28653000 | 169906000 |
| Monday, January 1, 2018 | 37734000 | 248932000 |
| Tuesday, January 1, 2019 | 41884000 | 354100000 |
| Wednesday, January 1, 2020 | 64435000 | 433300000 |
| Friday, January 1, 2021 | 57483000 | 583300000 |
| Saturday, January 1, 2022 | 70062000 | 752700000 |
| Sunday, January 1, 2023 | 52790000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing operational costs is crucial for sustained growth. This chart compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Over this period, Neurocrine Biosciences has seen a staggering increase in SG&A expenses, growing nearly 50 times from 2014 to 2023. In contrast, Ligand Pharmaceuticals experienced a more modest growth, with expenses increasing by approximately 130% over the same period.
The data reveals a significant divergence in spending strategies. Neurocrine's aggressive investment in administrative and selling capabilities may reflect its expansion efforts and market penetration strategies. Meanwhile, Ligand's steadier increase suggests a more conservative approach. This comparison offers a fascinating glimpse into how two companies navigate the financial demands of the biotech industry, each with its unique strategy and growth trajectory.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Jazz Pharmaceuticals plc and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends